All the Drug Class Drugs
Engineered Autologous T Cell Immunotherapy product. lisocabtagene maraleucel 1.1-70 x 10^6 cells/mL. Vial 1X 4.6 ml for IV inf.
For autologous use.
Tmt. of adults with large B-cell lymphoma (LBCL), incl. diffuse large B-cell lymphoma (DLBCL) not otherwise specif. (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have:
refract. dis. to first-line chemoimmunother. or relapse within 12 months of first-line chemoimmunother.;or
refract. dis. to first-line chemoimmunother. or relapse after first-line chemoimmunother. and are not eligible for hematopoetic stem cell transplant. (HSCT) due to comorbidities or age.
Tmt. of adults with relapsed or refract. diffuse large B-cell lymphoma(DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after two or more lines of syst. ther.
Tmt. of adults with relapsed or refract. follicular lymphoma (FL) after two or more lines of syst. ther.
Tmt. of adults with relapsed or refract. mantle cell lymphoma (MCL) after at least two lines of syst. ther. incl. a Bruton's tyrosine kinase (BTK) inhib.
C/I:Hypersens. Contraindic. of the lymphodepleting chemother. must be considered.
Engineered Autologous T Cell Immunotherapy product. Tisagenlecleucel . Dispers. for IV inf. cont. 10-30 ml or 30-50 ml.
Dosage in paed. and young adlt. CD19+ B-cell ALL pts. - For pts. under 50 kg : 0.2 to 5 x 106 CAR-posit. viable T cells/kg BW. - For pts. above 50 kg: 0.1 to 2.5 x 108 CAR-positive viable T cells (non-weight based). Dosage in adlt. DLBCL and FL pts. - 0.6 to 6.0 x 108 CAR-posit. viable T cells (non-weight based).
Paed. and young adlt. pts. up to and incl. 25 years of age with CD19+ B-cell acute lymphoblastic leukaemia (ALL) refract., in relapse post-transpl. or in second or later relapse. – Adlt. pts. with relapsed or refract. diffuse large B-cell lymphoma (DLBCL) after two or more lines of syst. ther. Limit of Use: not for tmt. of pts. with prim. or second. CNS lymphoma- Adlt. pts. with relapsed or refract. follicular lymphoma (FL) after two or more lines of syst. ther.
C/I: Hypersens. Also consider C/I of the lymphodepleting chemother.
Engineered Autologous T Cell Immunotherapy product. Axicabtagene Ciloleuce . BAG CRYOSTORE (Sol. for IV infus.):1. Dosage must be ajust. individ. See lit.
Tmt. of adult pts. with relapsed or refract. diffuse large B cell lymphoma. (DLBCL) and primary mediastin. large B cell lymphom. (PMBCL), after two or more lines of system. ther.
Limitation of Use: YESCARTA is not indicated for the tmt. of pts. with prim. or second. CNS lymphoma.
C/I: Hypersens.
Contraindications of the lymphodepleting chemother.must be considered.
